Antares Pharma Inc

Antares Pharma — Investor Presentation (August 2021)

28 slides from Antares Pharma's investor presentation, Aug 18, 2021

  1. Slide 1: August 2021 Investor Presentation

    1August 2021 NASDAQ: ATRS | August 2021 Investor Presentation EX99.1

  2. Slide 2: Safe Harbor Statement

    2August 2021 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results t

  3. Slide 3: Investment Highlights

    3August 2021 Leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Investment Highlights Diversified revenue provides opportunities for continued growth Commercial XYOSTED®, OTREXUP® and NOCDURNA® Commercial Generic Ep

  4. Slide 4: Long-Term Growth Strategy

    4August 2021 Long-Term Growth Strategy Expand Partnership Opportunities A leader in self-administered injection technology Support life-cycle management solutions Disciplined Capital Allocation Corporate development In-licensing opportunities Enhance Proprietary Portfolio Support research and develo

  5. Slide 5: Rapidly Growing and Diversified Revenue Mix

    5August 2021 42% 34% 10% 14% FY 2020 32% 43% 6% 20% FY 2019 28% 48% 11% 14% FY 2018 Rapidly Growing and Diversified Revenue Mix Proprietary Products Partner Products Development Royalty Revenue $63.6M Revenue $123.9M Revenue $149.6M 43% 22% 14% 21% YTD 2021 Revenue $87.1M

  6. Slide 6: Proprietary Products

    6August 2021 Proprietary Products (desmopressin acetate) sublingual tablet

  7. Slide 7: Patient-Centric Innovation Drives Strategy

    7August 2021 Patient-Centric Innovation Drives Strategy Targeting two therapeutic areas with significant market opportunities UROLOGY & ENDOCRINOLOGY Focus on patient populations with high unmet needs Target addressable physician audiences for efficient commercialization Identify and develop innovat

  8. Slide 8: XYOSTED (testosterone enanthate) for injection

    8 Innovative self-delivery of testosterone (T) replacement therapy for at-home use • T levels maintained for as long as the patient remains on therapy* • Convenient, once-a-week dosing • Virtually painless subcutaneous injection ~75% of all commercial lives covered 16 Orange Book listed patents thro

  9. Slide 9: Testosterone Market

    9August 2021 Testosterone Market Once Weekly Painless Efficacious Steady PK No Risk of Transfer 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 4,000,000 4,500,000 2020 TRT Growth: 6.8% 2020 TRT INJECTABLE Growth: 7.3% 2020 TRT Topical Growth: 1.0% 2020 TRT TRx: 7.6M 2020 TRT I

  10. Slide 10: XYOSTED Quarterly TRx Growth

    10August 2021 XYOSTED® Quarterly TRx Growth Written by ~9,300 different physicians (since launch) 2Q 2021 TRx’s increased >50% year-over-year 2Q 2021 TRx’s increased ~15% sequentially 3,207 6,485 10,290 14,064 16,777 17,685 21,461 23,274 24,493 27,961 796 4,517 8,893 13,638 16,387 20,589 22,536 26,5

  11. Slide 11: XYOSTED Broad Utilization Across Specialties

    11August 2021 Endocrinology 21% Primary Care 20% Urology 25% Nurse Practioners Physician Assistants 22% Other 12% XYOSTED® Broad Utilization Across Specialties 2Q 2021 IQVIA Data

  12. Slide 12: Focused Sales Effort to Optimize Current Portfolio

    12August 2021 • Branded TRT, Desmopressin/OAB and RA/MTX market • ~95% of TRT prescribers in the top 3 deciles is covered • ~88% of NOCDURNA® targets are also XYOSTED targets • ~98% of OTREXUP® volume is covered • Every territory has 120-150 top decile prescriber Recently expanded sales team • 85 SA

  13. Slide 13: In-Licensed: NOCDURNA (desmopressin acetate)

    13August 2021 FDA-approved vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times a night to void • First and only sublingual tablet that targets the kidneys • Short-acting desmopressin is underutilized due to poor disease state a

  14. Slide 14: NOCDURNA Works Quickly

    14August 2021 NOCDURNA® Works Quickly A sublingual tablet that dissolves rapidly1 Administered without water1 Onset action occurs within 30 minutes1 Therapeutic effect as early as the first night1 Elimination from the body starts quickly, within a half-life of 2.8 hours1 Antidiuretic effect lasts 6

  15. Slide 15: Antares Assets in Development

    15August 2021 ATRS-1901 Urology Asset Antares Assets in Development ATRS-1902 for Adrenal Crisis Rescue Completed Pre-IND meeting with FDA Filed IND with FDA in June 2021 Expect to initiate BC study followed by BE study Expect to file 505(b)(2) NDA with FDA towards the end 2022 ATRS-1901: Urology As

  16. Slide 16: ATRS-1902 for Adrenal Crisis Rescue

    16August 2021 ATRS-1902 for Adrenal Crisis Rescue + 62% 6% 6% 12% 14% ENDOCRINOLOGY PEDIATRICS NURSE PRACTITIONER PRIMARY CARE ALL OTHERS Solu-Cortef® Prescribers Simple (2-step), integrated device versus standard-of-care, Solu-Cortef® sterile powder that requires reconstitution and multiple steps L

  17. Slide 17: Partner Business

    17August 2021 Partner Business

  18. Slide 18: Pharmaceutical Technology Partner

    18August 2021 Deep Device Knowledge Drug/Device Combination Product Partner Extensive Regulatory Expertise and Success Tailored Durable Asset Development PHARMACEUTICAL TECHNOLOGY PARTNER $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 2015 2016 2017 2018 2019 2020 Partner Product License and Development Royalt

  19. Slide 19: Teva's Generic EpiPen Commercial Experience

    19August 2021 Commercial Experience Teva’s Generic EpiPen FDA-approved as therapeutically equivalent to Mylan’s EpiPen® and fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on net sales EpiPen, Jr. launched in

  20. Slide 20: Generic EpiPen Quarterly TRx Prescription Trends

    20August 2021 Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions 28,750 / 6% 125,000 / 22% 237,000 / 27% 183,000 / 36% 206,000 / 43% 176,000 / 38% 293,000 / 43% 232,000 / 48% 305,000 / 53% 445,000 / 58%448,750 568,000 862,000 506,000 484,000 465,000 676,000 483,000

  21. Slide 21: Generic Forteo (teriparatide)

    21August 2021 Teva launched ROW 11 European countries Israel and Canada Forteo® 2020 revenue $510 million in U.S. $536 million in ROW by Lilly Attractive economics to ATRS Supply devices at reasonable margin Royalties escalating to mid-teens Potential FDA approval Expect fully substitutable at pharm

  22. Slide 22: Global Development Agreement with Idorsia for selatogrel

    22August 2021 Global Development Agreement with Idorsia Pharmaceuticals for selatogrel, a New Chemical Entity, with the QuickShot® auto injector selatogrel Selatogrel is a potent and highly selective P2Y12 receptor antagonist intended for the treatment of suspected Acute Myocardial Infarction (AMI)

  23. Slide 23: Myocardial Infarction Market Opportunity

    23August 2021 • ~800,000 occurrences of new or recurrent MI1 annually • 600,000 have a first MI + 200,000 have a recurrent MI Myocardial Infarction Market Opportunity Mozaffarian D et al. Circulation 2016 * American Heart Association ~8.4 million Americans* have survived a Myocardial Infarction (MI)

  24. Slide 24: Diversified Product Portfolio

    24August 2021 Diversified Product Portfolio Testosterone Methotrexate Desmopressin Acetate Sumatriptan Epinephrine Hydroxyprogesterone Teriparatide Teriparatide Exenatide P2Y12 Receptor Antagonist Undisclosed Hydrocortisone Undisclosed XYOSTED® OXTREXUP® NOCDURNA® SUMATRIPTAN EPINEPHRINE MAKENA® TER

  25. Slide 25: Revenue Growth and 2021 Projections

    25August 2021 45% 50% 51% 59% 58% 62% 0% 10% 20% 30% 40% 50% 60% 70% 2016 2017 2018 2019 2020 YTD 2021 Gross Margin $52.2M $54.5M $63.6M $123.9M $149.6M $175-200M* 2016 2017 2018 2019 2020 2021 +4% vs. 2016 +21% vs. 2019 +17% vs. 2017 +95% vs. 2018 Revenue Growth and 2021 Projections Projected 5-Yea

  26. Slide 26: Income Statement Summary

    26August 2021 Income Statement Summary (in millions, except EPS) 2Q 2021 2Q 2020 Increase (Decrease) Total Revenue 45.0 32.4 39% Cost of Products Sales and Development Revenue 16.4 12.5 31% Total Gross Profit 28.6 19.9 44% Gross Margin 63% 61% --- R&D and SG&A Expenses 21.8 16.9 29% Net Income $4.4

  27. Slide 27: Antares Pharma: Value Proposition

    27August 2021 Antares Pharma: Value Proposition Diverse portfolio of commercialized products Multiple growth drivers • Continued XYOSTED® prescription growth • Continued generic EpiPen® prescription growth • Relaunch of NOCDURNA® • Potential FDA approval and U.S. launch of Teva’s generic teriparatid

  28. Slide 28: Thank You!

    Thank You! RR antares making medicines better” feel August 2021 28

Antares Pharma — Investor Presentation (August 2021) on 6ix